The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | NKG2D-based CAR-T in R/R AML and MDS
CYAD-01 is a natural killer group 2D (NKG2D)-based CAR T-cell product. David Sallman, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the latest results from the completed dose-escalation of the hematological arm of the phase I THINK study (NCT03018405), which evaluated the safety and clinical activity of multiple infusions CYAD‑01 without any prior preconditioning chemotherapy in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
